Rajesh RamachandranNair

Dr. Rajesh RamachandranNair


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Epilepsy & Behavior
Verified
Journal Article
Closed access
RRRajesh RamachandranNair
Rajesh RamachandranNair
SJSusan M. Jack
Susan M. Jack
BMBrandon F. Meaney
Brandon F. Meaney
GRGabriel M. Ronen
Gabriel M. Ronen

1 February 2008 in Epilepsy Research
Verified
Journal Article
Closed access
RRRajesh RamachandranNair
Rajesh RamachandranNair
AOAyako Ochi
Ayako Ochi
KIKatsumi Imai
Katsumi Imai
MBMony Benifla
Mony Benifla
TATomoyuki Akiyama
Tomoyuki Akiyama
HOHiroshi Otsubo
Hiroshi Otsubo

1 November 2016 in Epilepsy & Behavior
Verified
Journal Article
Closed access
RRRajesh RamachandranNair
Rajesh RamachandranNair
SJSusan M Jack
Susan M Jack

1 March 2016 in Epilepsy & Behavior
Verified
Journal Article
Closed access
RRRajesh RamachandranNair
Rajesh RamachandranNair
SJSusan M. Jack
Susan M. Jack
SSSonya Strohm
Sonya Strohm

17 February 2023 in Developmental Medicine & Child Neurology
Verified
Journal Article
Open access
RWRobyn Whitney
Robyn Whitney
SSSuvasini Sharma
Suvasini Sharma
RRRajesh RamachandranNair
Rajesh RamachandranNair
Sudden unexpected death in epilepsy (SUDEP) is the leading cause of epilepsy‐related mortality in children and adults living with epilepsy. The incidence of SUDEP is comparable in both children and adults; it is approximately 1.2 per 1000 person years. The pathophysiology of SUDEP is not well understood but may involve mechanisms such as cerebral shutdown, autonomic dysfunction, altered brainstem function, and cardiorespiratory demise. Risk factors for SUDEP include the presence of generalized tonic–clonic seizures, nocturnal seizures, possible genetic predisposition, and non‐adherence to antiseizure medications. Pediatric‐specific risk factors are not fully elucidated. Despite recommendations from consensus guidelines, many clinicians still do not follow the practice of counseling their patients about SUDEP. SUDEP prevention has been an area of important research focus and includes several strategies, such as obtaining seizure control, optimizing treatment regimens, nocturnal supervision, and seizure detection devices. This review discusses what is currently known about SUDEP risk factors and reviews current and future preventive strategies for SUDEP.

21 February 2024 in Genes
Verified
Journal Article
Open access
PDF file
HSHannah E. Snyder
Hannah E. Snyder
PJPuneet Jain
Puneet Jain
RRRajesh RamachandranNair
Rajesh RamachandranNair
KJKevin C. Jones
Kevin C. Jones
RWRobyn Whitney
Robyn Whitney
Infantile epileptic spasms syndrome (IESS) is a devastating developmental epileptic encephalopathy (DEE) consisting of epileptic spasms, as well as one or both of developmental regression or stagnation and hypsarrhythmia on EEG. A myriad of aetiologies are associated with the development of IESS; broadly, 60% of cases are thought to be structural, metabolic or infectious in nature, with the remainder genetic or of unknown cause. Epilepsy genetics is a growing field, and over 28 copy number variants and 70 single gene pathogenic variants related to IESS have been discovered to date. While not exhaustive, some of the most commonly reported genetic aetiologies include trisomy 21 and pathogenic variants in genes such as TSC1, TSC2, CDKL5, ARX, KCNQ2, STXBP1 and SCN2A. Understanding the genetic mechanisms of IESS may provide the opportunity to better discern IESS pathophysiology and improve treatments for this condition. This narrative review presents an overview of our current understanding of IESS genetics, with an emphasis on animal models of IESS pathogenesis, the spectrum of genetic aetiologies of IESS (i.e., chromosomal disorders, single-gene disorders, trinucleotide repeat disorders and mitochondrial disorders), as well as available genetic testing methods and their respective diagnostic yields. Future opportunities as they relate to precision medicine and epilepsy genetics in the treatment of IESS are also explored.